Keytruda Qlex-Pembrolizumab And Berahyaluronidase Alfa-Pmph
Keytruda Qlex is a subcutaneous formulation of pembrolizumab with berahyaluronidase alfa, approved across multiple solid tumor types. It delivers the same efficacy as IV Keytruda with a quick under-the-skin injection, reducing clinic time for patients.
Elfabrio-Pegunigalsidase Alfa-Iwxj
Elfabrio is the first PEGylated enzyme replacement therapy approved by the FDA for adults with Fabry disease. It provides exogenous alpha‑galactosidase A to reduce globotriaosylceramide accumulation and improve organ function.
Epkinly-Epcoritamab-Bysp
Epkinly is an injection used for certain types of blood cancer like large B-cell lymphoma. It helps immune cells find and destroy cancer cells.
Leqembi-Lecanemab-Irmb
Leqembi is a prescription medicine for early-stage Alzheimer’s disease. It’s a monoclonal antibody that helps reduce amyloid plaques in the brain and is the first treatment of its kind approved in the European Union.
Zynyz-Retifanlimab-Dlwr
Zynyz is the first PD‑1 inhibitor approved by the FDA for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal. It is now available both as monotherapy and in combination with platinum‑based chemotherapy, and is also approved for metastatic Merkel cell carcinoma; it enhances T‑cell activity to target and […]
Lamzede-Velmanase Alfa-Tycv
Lamzede is the first enzyme replacement therapy for non-central nervous system manifestations of alpha-mannosidosis. It improves enzyme activity and reduces the buildup of serum oligosaccharides.
Veopoz-Pozelimab-Bbfg
Veopoz is an antibody injection that treats CHAPLE disease, a rare genetic disorder causing protein loss and chronic intestinal inflammation. It works by blocking complement C5, helping to stabilize protein levels and reduce hospital visits in both children and adults.
Pombiliti-Cipaglucosidase Alfa-Atga
Pombiliti, used with Opfolda (miglustat), treats adults with late-onset Pompe disease who aren’t responding to enzyme replacement therapy. It delivers an enzyme to break down muscle-accumulated glycogen, improving muscle strength and lung function.
Rystiggo-Rozanolixizumab-Noli
Rystiggo is a weekly subcutaneous infusion for adults with generalized myasthenia gravis. It lowers harmful antibodies that disrupt communication between nerves and muscles.
Talvey-Talquetamab-Tgvs
Talvey is a bispecific antibody injection for adults with multiple myeloma who have already tried at least four other treatments. It helps the immune system target and kill myeloma cells.
